A Believe-It-or-Not Cancer Drug

CellAdam Is Successful, Natural, Ethical

By Edward Pentin

ROME, JAN. 22, 2009 (Zenit.org).- Imagine a medicine that has a staggering 75% success rate in treating cancer, and yet is a natural and ethical product, owned by a nonprofit company headed by devout Catholics.

Too good to be true? That's what I thought. The medical world is not short of bogus cancer "cures." Treatment for the disease is a multi-billion dollar industry that has led to questionable or unproven methods springing up throughout the world.

Yet this little-known product, which works by rebuilding the body's own adult stem cells and destroying tumour cells, already has a 25-year track record as a highly effective cancer treatment. Called CellAdam, it is most effective in preventing the early stages of cancer. But it also impedes the malignant process, and has an analgesic effect in the hopeless stage of an advanced tumour. Because of its natural composition, it has none of the hallucinogenic effects you get with morphine. The ingredients simply include a fatty acid complex extracted from soy and sunflower.

"This is a totally unusual and huge breakthrough," says Dr. Thomas Janossy, president of Biostemworld, the company producing the drug internationally. "In the next two to three years, it will become the first anti-cancer prescription drug in the world that is nature-based."
So why has hardly anyone heard of it? According to Biostemworld, the reason is because it was developed in Hungary during the country's Communist era. CellAdam was discovered, by chance, by Adam Kovacs, a Christian Hungarian researcher, who put his whole life into finding a cure for cancer.

Imre Beke, Biostemworld's chairman, calls it a "diamond in disguise" because of the numerous obstacles that have prevented this drug from reaching a wider market.

The first hindrance has been the Hungarian language. "As the researchers of this drug only speak Hungarian, it's not been widely published in international media and so nobody really knows about it," says Beke. Then there was the country's Communist past and personal rivalries that remained even after the fall of the Berlin Wall.

Breaking out

"Envy, old skirmishes and conflicts, pharmaceutical companies worried about losing their market share in the cancer business -- which is huge -- all played a part," Beke explains. Moreover, Kovacs was a medical assistant and not part of the Hungarian medical establishment. The country's medical professionals, perhaps envious of his discovery, always blocked the drug from wider distribution.

"Now", says Beke, "we're really breaking out."

I caught up with Beke, Janossy and their public relations officer, Maria Dalgarno, while they were visiting Rome earlier this month. They were staying, it should be noted, not at the Hilton, but at the modest Generalate of the Sons of the Immaculate Conception. Their purpose was to meet members of a Catholic hospital run by a religious order whose charism is to help the sick.

The company wants the order, which has 400 cancer researchers in Italy, to carry out human and animal research on the medicine. They wouldn't name the order as negotiations are still continuing, but the hope is it will carry out more quantitative analysis to make the alternative therapy more viable. It can then also be formally classed as a drug, have more credibility and be distributed more widely.

The Catholic factor in this is significant. Rather than make large profits from CellAdam, the company wants to plough all revenues made from the drug back into research, or to help Church missions. "We had a lot of opportunities to sit down with many medical research centers," says Janossy. "But the inventor, who is a Christian, was looking for people who spoke Hungarian, were Christian-Catholic, and who had scientific and business backgrounds. Somehow we got together."

Janossy says the company steered clear of the United States because of its heavily profit-oriented pharmaceutical industry, and instead looked toward this Italian Catholic hospital. "Their whole approach to healing is so different," Janossy says. "The president is a priest who's not picking up a salary. All the profit goes back to research or is sent to the missions. That is extremely unique. So we said, 'OK we will share this product and the potential it has.'"


Once any cancer drug hits the market, it can generate revenues of hundreds of millions of dollars. Biostemworld is expecting CellAdam will generate over a billion dollars once it becomes fully viable in about two to three years. "It's huge," says Janossy, "but we want the profit to be shared or managed by a Catholic interest where the hope is that the profit will help the people in need. It's a very unusual approach."

So what evidence is there that this drug really works? Apparently, there is no shortage of testimonies, in addition to the company's claim that it has a 75% success rate. There is a bus driver in Hamilton, Canada, who has just found out that after taking CellAdam for less than a month, a 5-centimeter tumour has been reduced to the size of pea and now he doesn't have to worry about having chemotherapy.

There is the case of a woman with lung cancer -- the hardest kind to treat -- which had become so bad that she had gone home to die. "She started to take CellAdam and within two months she was practically clear," says Janossy.

"Constantly, every couple of days, there are these dramatic cases." Janossy says an ongoing 10-year study in Hungary is currently focusing on two groups of cancer sufferers. One group, who all went through chemotherapy, have since died, but those who have been taking CellAdam are still alive.

CellAdam works by breaking down a shield that is preventing cancer cells from communicating with the body's natural immune system, allowing it to kill the cancer cells. "It is putting back your immune system into balance," explains Beke, "assisting your immune system to cure the cancer, enhancing your own system to be natural and letting a natural process take over a sick body." Certain cells react better than others to the drug, such as breast, lung and large intestinal cancer cells, melanoma malignum and certain types of obstetric tumours. But even large tumours can be blocked by CellAdam, claims Biostemworld.

It's best track record, however, is as a cancer prevention therapy. When used as a dietary supplement, it works by building up the body's adult stem cell count. Stem cells can decrease by as much as 80% in the course of a lifetime, leading to signs of ageing, a weakened immune system, and diseases such as cancer. With CellAdam and its other nature-based drugs, Biostemworld claims it can restore that count by as much as 75%, exceeding a similar product in California by 50%. Not only do they prevent cancer, but other diseases too.

Furthermore, Biostemworld argues its products are without the dangers associated with synthetic drugs because they are less toxic. Janossy says pharmaceutical companies prefer synthetic drugs because they are easier to patent and so make more money. But he adds that synthetic drugs tend to mimic what is already available in natural drugs, some of which have been used in countries such as China for over 4,000 years.

But perhaps the most persuasive proof of this drug's effectiveness is the belief among those running Biostemworld that this discovery is Providential. Global cancer deaths are expected to rise by 45% by 2030, overtaking cardio-vascular disease as the biggest cause of death, and putting great strain on health services and society. "We feel in a lot of ways that Our Lady has really inspired us," says Maria Dalgarno who is also a member of the Catholic movement Focolare. "[Governments] know the system can't manage it -- they've said it. There's no way they can take care of all those people."

She pointed to the growth of euthanasia, which is gaining popularity in the West as demand for health care for the elderly increases. "My first thought when this company was forming was: bingo, this had to come because the medical establishment is saying: 'What are we going to do with all these old people?'"

Dalgarno felt it was "truly God's work," not only because it could help counter the push toward euthanasia, but also because their products are less expensive, less dangerous and more ethical. Embryonic stem cell research plays no part in this medicine.

"We put our work daily under the protection of Our Lady," says Dalgarno, "knowing she is guiding our work and the 'mission in the health field' that we feel called to."

Like the Good News, this does seem too good to be true, but perhaps that just shows that this drug really does have the Divine hand behind it.

More details on CellAdam and Biostemworld's other nature-based disease prevention products can be found at: http://biostemworld.com/portal/

* * *

Edward Pentin is a freelance writer living in Rome. He can be reached at: epentin@zenit.org.